Deferred Revenue (Tables)

12 Months Ended

Dec. 31, 2018

Deferred Revenue Disclosure [Abstract]

Schedule of Deferred Revenue Activity

The following is a summary of the Company’s deferred revenue activity for the year ended December 31, 2018, the five months ended December 31, 2017 and the year ended July 31, 2017:

(in thousands)	NIH Grant				BED			Other Opioid Treatments			Total
Balance as of July 31, 2016		$	—		$	1,000		$	1,600		$	2,600
Recognized as revenue		—			(39		)	—			(39		)
Balance as of July 31, 2017		—			961			1,600			2,561
Recognized as revenue		—			(66		)	—			(66		)
Balance as of December 31, 2017		—			895			1,600			2,495
Cash Received NIH		1,000			—			—			1,000
Converted to Equity		—			—			(1,600		)	(1,600		)
Recognized as revenue		(432		)	(251		)	—			(683		)
Balance as of December 31, 2018		$	568		$	644		$	—		$	1,212

Deferred Revenue, by Arrangement

urrent and long-term deferred revenue are detailed in the following table:

Deferred Revenue (in thousands)	NIH Grant			BED		Other Opioid Treatments		Total
Current portion		$	568	$	644	$	—	$	1,212
Long-term portion		—		—		—		—
Total		$	568	$	644	$	—	$	1,212